4D Molecular Therapeutics: This Gene Therapy Company May Soon Surprise Investors

D Molecular Therapeutics (FDMT) offers attractive growth potential with strong cash reserves and promising late-stage gene ...
Nasdaq

4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program

EMERYVILLE, Calif., Feb. 08, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT; 4DMT or the Company), a leading clinical-stage company focused on unlocking the full potential of genetic ...
Benzinga.com

Why Is Eye Disease-Focused 4D Molecular Therapeutics Stock Shooting Higher Today?

4D Molecular Therapeutics (NASDAQ:FDMT) shares are trading higher after the company released interim data from the Phase 2 PRISM clinical trial evaluating intravitreal 4D-150 in wet age-related ...
GMA Network

4D Lotto

FOR more info, visit the PCSO 4D Lotto page.
Yahoo Finance

Jim Cramer on 4D Molecular Therapeutics: “This is a Pure Spec”

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) is one of the stocks Jim Cramer answered questions about recently. A caller asked Cramer for his opinion on the stock, and noted that it was rated a ...